107 related articles for article (PubMed ID: 2001875)
1. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
Kawai T; Suzuki M; Torikata C; Suzuki Y
Hum Pathol; 1991 Feb; 22(2):118-24. PubMed ID: 2001875
[TBL] [Abstract][Full Text] [Related]
2. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
3. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
4. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
Attanoos RL; Webb R; Gibbs AR
Histopathology; 1997 Mar; 30(3):260-3. PubMed ID: 9088956
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
6. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
Attanoos RL; Goddard H; Gibbs AR
Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
[TBL] [Abstract][Full Text] [Related]
7. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
8. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
10. [Pseudomesotheliomatous adenocarcinoma of the lung. Immunohistochemical study with special reference to detection of blood group isoantigens and Ber-EP4 antigen].
Moch H; Kiener S; Dalquen P; Gudat F
Pathologe; 1993 Jan; 14(1):11-5. PubMed ID: 8095719
[No Abstract] [Full Text] [Related]
11. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
12. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
13. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
[TBL] [Abstract][Full Text] [Related]
14. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
Otis CN; Carter D; Cole S; Battifora H
Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
[TBL] [Abstract][Full Text] [Related]
19. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]